Cobra Venom Factor

Uniform pool of Cobra Venom Factor (CVF), a non-toxic complement activating reagent.


Product Specifications

Citations 27
Description

Uniform pool of Cobra Venom Factor (CVF), a non-toxic complement activating reagent.

Storage Store at -70°C or below. Minimize freeze/thaw cycles.
Form

Frozen liquid (Phosphate Buffered Saline, pH 7.2 ± 0.2)

Concentration 1.0-1.2 mg/mL
Applications

See citations and technical data sheet for application info.

Ordering Information

For Research Use Only. Not for use in diagnostic procedures.
Catalog Number A600
Catalog Number (CE) N/A
Size 1.0 mg
Price (USD) $400.00
Price (EURO) 355,00 €

Contact us

US Phone+1 (858) 552 1100
EU Phone+353 (91) 412 474
US Emailcontact-us@quidelortho.com
EU Emailcontact-emea@quidelortho.com

Specifications

Description

Uniform pool of Cobra Venom Factor (CVF), a non-toxic complement activating reagent.

Size 1.0 mg
Storage

Store at -70°C or below. Minimize freeze/thaw cycles.

Form Frozen liquid (Phosphate Buffered Saline, pH 7.2 ± 0.2)
Concentration 1.0-1.2 mg/mL
Applications See citations and technical data sheet for application info.
Purity ≥ 95% by SDS page
Source

Naja naja kaouthia (cobra)

Activity 8 units/mL to 20 units/mL for full complement conversion.
Molecular Weight N/A
Background

Cobra Venom Factor (CVF), sometimes referred to as C3b(Cobra), is the non-toxic, complement activating component of cobra venom. Like naturally occurring C3b, CVF forms a complex with complement components Factor B and Factor D. This CVFBbD convertase is capable of activating C3 in a wide variety of species via the alternative complement pathway. Unlike the naturally occurring convertase (C3bBbD), the C3b(Cobra)BbD convertase is Factor H resistant and is therefore not inactivated by Factor I or CR1. Given appropriate incubation time, CVF will convert nearly 100% of the C3 to C3 end products. Unlike CVF purified from the Naja naja haje species, CVF from Naja naja kaouthia activates the terminal pathway directly by forming a C5 convertase. This depletes C5 in a manner analogous to that described above for C3. Levels of iC3b, C3a, SC5b-9, C5a and the Factor B cleavage product Bb are all extremely high in CVF treated sera.

Citations

Title Year Applications Sample Species Sample Sample Details

Up to 9-day survival and control of thrombocytopenia following alpha1,3-galactosyl transferase knockout swine liver xenotransplantation in baboons

2012

Complement Depletion Assay

Baboon

Protein Injection

Chimeric 2C10R4 anti-CD40 antibody therapy is critical for long-term survival of GTKO.hCD46.hTBM pig-to-primate cardiac xenograft

2016

Complement Depletion Assay

Baboon

Protein Injection

Graphene Oxide Nanosheets for Localized Hyperthermia-Physicochemical Characterization, Biocompatibility, and Induction of Tumor Cell Death.

2020

Complement Activation Assay

Human

Plasma

Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles

2009

Complement Activation Assay

Human

Plasma

Gold Nanoparticles incubated

Zwitterionic chitosan derivatives for pH-sensitive stealth coating

2010

Complement Activation Assay

Human

Plasma

Nanoparticles size-dependently initiate self-limiting NETosis-driven inflammation

2016

Complement Activation Assay

Human

Serum

Soluble MAC is primarily released from MAC-resistant bacteria that potently convert complement component C5.

2022

Complement Depletion Assay

Human

Serum

Molecular response of chorioretinal endothelial cells to complement injury: implications for macular degeneration

2016

Complement Depletion Assay

Human

Serum

Discovery of monoclonal antibodies cross-reactive to novel subserotypes of K. pneumoniae O3

2017

Complement Depletion Assay

Human

Serum

A Conformational Change of Complement C5 Is Required for Thrombin-Mediated Cleavage, Revealed by a Novel Ex Vivo Human Whole Blood Model Preserving Full Thrombin Activity.

2021

WB

Human

Purified protein

The role of innate immune responses in the outcome of interspecies competition for colonization of mucosal surfaces

2005

Complement Depletion Assay

Mouse

Protein Injection

Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV

2008

Complement Depletion Assay

Mouse

Protein Injection

Natural antibody to conserved targets of Haemophilus influenzae limits colonization of the murine nasopharynx

2009

Complement Depletion Assay

Mouse

Protein Injection

Complement promotes the development of inflammatory T-helper 17 cells through synergistic interaction with Toll-like receptor signaling and interleukin-6 production

2009

Complement Depletion Assay

Mouse

Protein Injection

SIGN-R1, a C-type lectin, enhances apoptotic cell clearance through the complement deposition pathway by interacting with C1q in the spleen

2013

Complement Depletion Assay

Mouse

Protein Injection

Cutting edge: the NLRP3 inflammasome links complement-mediated inflammation and IL-1β release

2013

Complement Depletion Assay

Mouse

Protein Injection

Yersinia pseudotuberculosis uses Ail and YadA to circumvent neutrophils by directing Yop translocation during lung infection

2014

Complement Depletion Assay

Mouse

Protein Injection

C3 dysregulation due to factor H deficiency is mannan-binding lectin-associated serine proteases (MASP)-1 and MASP-3 independent in vivo

2014

Complement Depletion Assay

Mouse

Protein Injection

Efficiency of conditionally attenuated Salmonella enterica serovar Typhimurium in bacterium-mediated tumor therapy

2015

Complement Depletion Assay

Mouse

Protein Injection

Endotoxin neutralization by an O-antigen specific monoclonal antibody: A potential novel therapeutic approach against Klebsiella pneumoniae ST258

2017

Complement Depletion Assay

Mouse

Protein Injection

Complement Depletion Improves Human Red Blood Cell Reconstitution in Immunodeficient Mice

2017

Complement Depletion Assay

Mouse

Serum

Intravital immunofluorescence for visualizing the microcirculatory and immune microenvironments in the mouse ear dermis

2013

IF

Mouse

Ear dermis Tissue

Treatment with Cobra Venom Factor Decreases Ischemic Tissue Damage in Mice

2024

Complement depletion assay

Mouse

Serum

Tissue ischemia

No expression of porcine endogenous retrovirus after pig to monkey xenotransplantation

2014

Complement Depletion Assay

Porcine

Protein Injection

Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques

2015

Complement Depletion Assay

Rat

Protein Injection

Complement-independent retinal pathology produced by intravitreal injection of neuromyelitis optica immunoglobulin G

2016

Complement Depletion Assay

Rat

Protein Injection

Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies

2016

Complement Depletion Assay

Rat

Protein Injection